Transcriptional signatures of the BCL2 family for individualized acute myeloid leukaemia treatment
ConclusionsThis study proposes BFSigs as a biomarker for the effective selection of apoptosis targeting treatments and cancer pathways to co-target in AML.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Genetics | Leukemia | Lymphoma | Nanotechnology | Study